• Molecular characterisation of low-grade serous ovarian cancer. Low-grade serous cancer is a subtype of ovarian cancer that often occurs in younger women and is resistant to chemotherapy. We are using next-generation sequencing to characterise activating mutations that can be targeted by novel pathway inhibitors.
  • Identification of molecular markers of response to chemotherapy and endocrine treatment. We are using a range of techniques including RNAseq and PCR arrays to identify markers that will assist in the selection of treatment for relapsed disease in ovarian cancer.
  • Application of molecular testing in the clinical environment. INOVATe (Individualised Ovarian Cancer Treatment through Integration of Genomic Pathology into Multidisciplinary Care) is a program of research aimed at implementing extensive molecular characterisation of ovarian tumours in a routine clinical setting to triage patients into novel clinical trials of targeted agents.